A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (NCT06966700)
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is a type of targeted therapy. A targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. The main goals of this study are to learn if people who receive sac-TMT, pembrolizumab, and chemotherapy: * Have fewer cancer cells found in the tumors and lymph nodes removed during surgery compared to those who receive only pembrolizumab and chemotherapy * Live longer without the cancer growing, spreading, or coming back compared to people who receive only pembrolizumab with chemotherapy
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (321 Sites)
Showing the first 25 of 321 sites.
- Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona
- Mayo Clinic Cancer Center ( Site 0034) — Phoenix, Arizona
- University of Arizona Cancer Center ( Site 0035) — Tucson, Arizona
- Roy and Patricia Disney Family Cancer Center ( Site 0055) — Burbank, California
- Community Cancer Institute ( Site 0100) — Clovis, California
- Providence Medical Foundation ( Site 0080) — Fullerton, California
- MemorialCare Health System - Long Beach Medical Center ( Site 9556) — Long Beach, California
- El Camino Hospital Cancer Center ( Site 0096) — Mountain View, California
- Hoag Memorial Hospital Presbyterian ( Site 0010) — Newport Beach, California
- Helios Clinical Research ( Site 0061) — Whittier, California
- Intermountain Health Cancer Center Saint Joseph ( Site 0062) — Denver, Colorado
- Rocky Mountain Cancer Centers (RMCC) ( Site 8006) — Denver, Colorado
- Intermountain Health St. Mary's Regional Hospital ( Site 0054) — Grand Junction, Colorado
- AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) — Altamonte Springs, Florida
- Florida Cancer Specialists - South ( Site 7004) — Fort Myers, Florida
- Bioresearch Partner ( Site 0072) — Hialeah, Florida
- Mayo Clinic Hospital ( Site 0013) — Jacksonville, Florida
- Florida Cancer Specialists - North ( Site 7002) — St. Petersburg, Florida
- City of Hope Cancer Center - Atlanta ( Site 0102) — Newnan, Georgia
- Fort Wayne Medical Oncology and Hematology ( Site 0084) — Fort Wayne, Indiana
- Franciscan Health ( Site 0077) — Indianapolis, Indiana
- Ochsner Clinic Foundation ( Site 0021) — New Orleans, Louisiana
- Louisiana State University Health Sciences Shreveport ( Site 0053) — Shreveport, Louisiana
- New England Cancer Specialists ( Site 0051) — Westbrook, Maine
- Mercy Medical Center - Baltimore ( Site 0015) — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.